High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$49K
$49,704
Total Sells (Filtered)
$13.9M
$13,905,279
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
| CRSP |
CRISPR Therapeutics AG
|
CEO
Sell to Cover
|
2026-02-19 | $366,325 | S | Form 4 |
|
CRSP
S
CRISPR Therapeutics AG
KASINGER JAMES R.
• Officer • General Counsel and Secretary
Sell to Cover
2026-02-19
$111,049
|
||||||
| CRSP |
CRISPR Therapeutics AG
|
Officer • General Counsel and Secretary
Sell to Cover
|
2026-02-19 | $111,049 | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CFO
10b5-1 SellΔOwn -83.8%
|
2026-01-22 | $2,104,965Large | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CFO
Other
|
2026-01-22 | $1,578,986Large | M | Form 4 |
|
CRSP
S
CRISPR Therapeutics AG
Kulkarni Samarth
• CEO
10b5-1 SellΔOwn -30.9%
2026-01-22
$3,613,800Large
|
||||||
| CRSP |
CRISPR Therapeutics AG
|
CEO
10b5-1 SellΔOwn -30.9%
|
2026-01-22 | $3,613,800Large | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CEO
10b5-1 Sell
|
2026-01-20 | $446,341 | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CEO
10b5-1 Sell
|
2026-01-20 | $1,106,157Large | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CFO
Other
|
2026-01-06 | $1,054,749Large | M | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CFO
Other
|
2026-01-06 | $280,881 | M | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CFO
10b5-1 SellΔOwn -51.9%
|
2026-01-06 | $1,139,386Large | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CFO
10b5-1 SellΔOwn -28.5%
|
2026-01-06 | $300,240 | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CFO
10b5-1 SellΔOwn -46.0%
|
2026-01-06 | $347,010 | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CFO
Equity Compensation
|
2026-01-06 | $0 | M | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CFO
Equity Compensation
|
2026-01-06 | $0 | M | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CFO
10b5-1 SellΔOwn -12.9%
|
2025-12-22 | $56,886 | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CFO
10b5-1 SellΔOwn -41.3%
|
2025-12-22 | $308,262 | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CFO
10b5-1 SellΔOwn -21.0%
|
2025-12-22 | $194,401 | S | Form 4 |
|
CRSP
S
CRISPR Therapeutics AG
Kulkarni Samarth
• CEO
Sell to CoverΔOwn -16.7%
2025-10-17
$3,456,279Large
|
||||||
| CRSP |
CRISPR Therapeutics AG
|
CEO
Sell to CoverΔOwn -16.7%
|
2025-10-17 | $3,456,279Large | S | Form 4 |
| CRSP |
CRISPR Therapeutics AG
|
CEO
Sell to Cover
|
2025-10-14 | $282,517 | S | Form 4 |
|
CRSP
S
CRISPR Therapeutics AG
KASINGER JAMES R.
• Officer • General Counsel and Secretary
Sell to Cover
2025-10-14
$71,662
|
||||||
| CRSP |
CRISPR Therapeutics AG
|
Officer • General Counsel and Secretary
Sell to Cover
|
2025-10-14 | $71,662 | S | Form 4 |
|
CRSP
P
CRISPR Therapeutics AG
Patel Naimish
• Officer • Chief Medical Officer
Discretionary Buy
2025-04-03
$49,704
|
||||||
| CRSP |
CRISPR Therapeutics AG
|
Officer • Chief Medical Officer
Discretionary Buy
|
2025-04-03 | $49,704 | P | Form 4 |